{"id":4076,"date":"2019-02-12T17:11:52","date_gmt":"2019-02-12T11:41:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4076"},"modified":"2024-09-18T15:03:37","modified_gmt":"2024-09-18T09:33:37","slug":"notizia-90","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-90","title":{"rendered":"Antidepressant of J&#038;J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways"},"content":{"rendered":"\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>The nasal antidepressant of <\/strong><strong>Johnson &amp; Johnson leads to FDA committee<\/strong><\/p>\n\n\n\n<p>The <strong>antidepressant<\/strong> esketamine of <strong>Johnson &amp; Johnson<\/strong> heads to <strong>FDA <\/strong>panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the <g class=\"gr_ gr_25 gr-alert gr_gramm gr_inline_cards gr_disable_anim_appear Grammar only-ins replaceWithoutSep\" id=\"25\" data-gr-id=\"25\">refractory<\/g> <strong>major depressive disorder (MDD)<\/strong> if FDA gives a nod to it. This would provide a new alternative for people, who could not control symptoms though after receiving drug therapy. <\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>New small cell lung cancer model discloses vital role of\ntwo mutated genes<\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">Small cell lung cancer (SCLC)<\/a><\/strong> develops in people who smoke often and it becomes resistant to <strong>chemotherapy <\/strong>and radiation. The disease is contemplated to emerge from pulmonary neuroendocrine cells (PNECs). The researchers from <strong>Weill Cornell Medicine in New York<\/strong> have found the way of growing PNECs from <strong>human embryonic stem cells<\/strong>. They have figured out the two genes that are commonly mutated in SCLC.<\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>The insights on genes and macular degeneration can\ndisclose new treatment ways<\/strong><\/p>\n\n\n\n<p>The <strong>National Institutes of Health&#8217;s&nbsp;National Eye Institute (NEI)<\/strong> has been questing for novel ways to use the genetic underpinnings of <a href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market\">age-related macular degeneration (AMD)<\/a>, a leading cause of blindness. The scientists at the NEI found <strong>52 <\/strong>genetic variants that are associated with AMD. They contemplate that their findings could produce fresh ideas for disease-modifying treatments in AMD.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The nasal antidepressant of Johnson &amp; Johnson leads to FDA committee The antidepressant esketamine of Johnson &amp; Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refractory major depressive disorder (MDD) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2558],"industry":[17225],"therapeutic_areas":[17229,17245,17228,17244],"class_list":["post-4076","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amd","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antidepressant of J&amp;J leads to FDA; SCLC model discloses<\/title>\n<meta name=\"description\" content=\"The antidepressant esketamine of Johnson &amp; Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-90\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antidepressant of J&amp;J leads to FDA; SCLC model discloses\" \/>\n<meta property=\"og:description\" content=\"The antidepressant esketamine of Johnson &amp; Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-90\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-12T11:41:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:33:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antidepressant of J&J leads to FDA; SCLC model discloses","description":"The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-90","og_locale":"en_US","og_type":"article","og_title":"Antidepressant of J&J leads to FDA; SCLC model discloses","og_description":"The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-90","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-02-12T11:41:52+00:00","article_modified_time":"2024-09-18T09:33:37+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-90","url":"https:\/\/www.delveinsight.com\/blog\/notizia-90","name":"Antidepressant of J&J leads to FDA; SCLC model discloses","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-90#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-90#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","datePublished":"2019-02-12T11:41:52+00:00","dateModified":"2024-09-18T09:33:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-90"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-90#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","width":1200,"height":630,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AMD<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AMD<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Feb 12, 2019","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Feb 12, 2019 5:11 pm","modified":"Updated on Sep 18, 2024 3:03 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4076"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4076\/revisions"}],"predecessor-version":[{"id":29614,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4076\/revisions\/29614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3711"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4076"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4076"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}